Company intelligence / Profile preview

rhute

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Rhute is a biotechnology company dedicated to developing the next generation of precision medicines for neurological and psychiatric disorders. The company leverages genetic insights and advanced molecular biology to target specific pathways involved in brain health and disease. Founded by industry veterans, including Richard Scheller, Rhute aims to overcome traditional challenges in neuroscience drug discovery by focusing on genetically validated targets. Their approach integrates deep biological understanding with modern drug development techniques to create transformative therapies for patients with high unmet needs.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on rhute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhute.

Explore the full profile